Langerhans Cell Histiocytosis Clinical Trial
Official title:
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With Relapsed and Refractory (R/R) Langerhans Cell Histiocytosis
This is a single-arm study to evaluate the efficacy and safety of CD207 targeted CAR-T cell therapy in relapsed and refractory langerhans cell histiocytosis.
Status | Not yet recruiting |
Enrollment | 12 |
Est. completion date | August 1, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Relapsed or refractory langerhans cell histiocytosis, defined as: 1) any relapse during standard chemotherapy; 2) not responding to standard chemotherapy; 3) not achieving CR after first cycle of second-line chemotherapy for relapsed langerhans cell histiocytosis; 2. 3-65 years old; 3. Expected survival time = 3 months; 4. ECOG performance status of 0 or 1 (age = 16 years) or Karnofsky performance status> 80 (age < 16 years) ; 5. With single or venous blood collection standards, and no other cell collection contraindications; 6. WBC = 2.5×10^9/L ,LY = 0.7×10^9/L,LY% =15%; 7. Serum creatinine = 2.0 mg/dl; 8. ALT/AST = 2.5 x ULN; 9. Total bilirubin = 2.0 mg/dl; 10. PT:INR<1.7, or PT is within 4s of the normal value; 11. Ability and willingness to adhere to the study visit schedule and all protocol requirements. Exclusion Criteria: 1. Transduced CAR+ T lymphocytes<5%, or expansion <5 folds after stimulation with anti CD3/anti CD28 beads; 2. Pregnant or breasting-feeding women; 3. Active hepatitis B or hepatitis C infection; 4. Patients with HIV infection; 5. Uncontrolled active infection; 6. Use of systemic corticosteroid therapy; 7. Have received gene therapy, or any other CAR-T treatment; 8. Allergic to immunotherapy and related drugs; 9. History of heart disease requiring treatment, or poorly controlled hypertension; 10. Preceding and/or ongoing active ulcer or gastrointestinal bleeding; 11. Have received allogeneic hematopoietic stem cell transplantation, or eligible for allogeneic hematopoietic stem cell transplantation; 12. Severe central nervous system involvement; 13. Severe lung involvement; 14. Hyponatremia (serum sodium<125mmol/L); 15. Hypokalemia (Serum kalium<3.5mmol/L); 16. Those who need long-term anticoagulation treatment (warfarin or heparin); 17. Those who need long-term antiplatelet treatment (aspirin, dose>300mg/d; clopidogrel, dose>75mg/d); 18. Radiation therapy within 4 weeks prior to registration; 19. Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina, cardiac arrhythmias, mental illness, and other diseases that in the opinion of the investigator would pose an unacceptable risk to the subject; 20. Have a history of severe allergy; 21. Current enrollment in another study; 22. Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement). |
Country | Name | City | State |
---|---|---|---|
China | Beijing Friendship Hospital, Capital Medical University | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Friendship Hospital | Beijing Boren Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate (ORR) | The number of cases with complete response (CR) and partial response (PR) after treatment as a percentage of the total cases. | 2 years | |
Primary | Incidence and Severity of Adverse Events (AEs) | Treatment-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) | 2 years | |
Secondary | Progression Free Survival (PFS) of CD207 CAR-T cell therapy in patients with r/r langerhans cell histiocytosis | PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression. | 2 years | |
Secondary | Overall Survival (OS) of CD207 CAR-T cell therapy in patients with r/r langerhans cell histiocytosis | OS will be assessed from the first CAR-T cell infusion to death from any cause. | 2 years | |
Secondary | Effects of CD207 CAR-T cells on human immune system | Dynamic changes of T cell subset and immune globulin. | 2 years | |
Secondary | Metabolism of CAR T-cells in vivo | Absorption, distribution and metabolism of CD207-CAR T cells in vivo. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03270020 -
Denosumab for the Treatment of Adult LCH
|
Phase 2 | |
Recruiting |
NCT05997602 -
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
|
Phase 2 | |
Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
Completed |
NCT03096782 -
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
|
Phase 2 | |
Recruiting |
NCT04120519 -
Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis
|
Phase 2 | |
Recruiting |
NCT04121819 -
AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis
|
Phase 2 | |
Recruiting |
NCT05284942 -
Central China Rosai-Dorfman Disease Registry
|
Phase 4 | |
Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT02608619 -
Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
|
||
Completed |
NCT01395004 -
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
|
Phase 2 | |
Recruiting |
NCT02205762 -
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02425904 -
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
|
Phase 2 | |
Recruiting |
NCT02670707 -
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
|
Phase 3 | |
Completed |
NCT02665546 -
Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis
|
||
Recruiting |
NCT04627090 -
LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study
|
||
Recruiting |
NCT03585686 -
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
|
Phase 2 | |
Recruiting |
NCT03155620 -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
|
Phase 2 | |
Recruiting |
NCT04773366 -
A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol
|
Phase 3 | |
Completed |
NCT02389400 -
Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis
|
Phase 2 | |
Completed |
NCT00588536 -
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
|
Phase 2 |